


NCATS Strategic Planning

Dorit Zuk, Ph.D.
Director, OPCSA

NCATS Council/CAN Review Board Meeting
September 3rd, 2015

NCATS



Strategic planning pool

REPORTS

- > Frequently Requested Reports
- > Biennial Report of the NIH Director
- > NIH Factsheets
- > Strategic Plans**
- > Recovery Act Investment Reports
- > NIH ARRA Stories
- > NIH Intramural Research Reports
- > The National Academies:
NIH-Funded Reports
- > Other Special Reports
- > Report Catalog
- > Links

QUICK LINKS

- RePORTER
- AWARDS BY LOCATION
- NIH DATA BOOK
- FUNDING FACTS
- RECOVERY ACT ON RePORT
- NIH FACT SHEETS
- NIH CATEGORICAL SPENDING
- BIENNIAL REPORT
- REPORT CATALOG

[Home](#) > [Research](#) > NIH Strategic Plans and Visions




NIH Strategic Plans and Visions

Institutes and Centers	NIH-Wide	Topical	Interagency Plans
 Center for Information Technology (CIT)	 Center for Scientific Review (CSR)	 John E. Fogarty International Center for Advanced Learning and Leadership in Health Sciences	 National Cancer Institute (NCI)
 National Center for Complementary and Alternative Medicine	 National Eye Institute (NEI)	 National Heart, Lung, and Blood Institute (NHLBI)	 National Human Genome Research Institute (NHGRI)
 National Institute of Allergy and Infectious Diseases (NIAID)	 National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	 National Institute of Biomedical Imaging and Bioengineering (NIBIB)	 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

<http://report.nih.gov/strategicplans/index.aspx>

Strategic Planning Process Timeline




Stage 1 - Internal NCATS Discussion

- Small group discussions with all NCATS staff about NCATS' vision and foundational strategy
 - Dec 2014-April 2015: 27 meetings, 252 staff
- Feedback analysis underway
- Will inform the development of the strategic plan



Stage 2 - Gathering Feedback from External Stakeholders




- Stakeholders include among others:
 - Patients and members of the health advocacy community
 - Basic, translational and clinical scientists at universities and research institutions
 - Biotechnology and pharmaceutical industry members
 - NIH colleagues
 - Other government agencies (e.g., FDA, EPA, DoD)
 - Policy-makers and funders
 - As well as the general public
- August - calls with NCATS staff and Council/CAN RB members to develop the key strategic planning topics

Proposed Thematic Areas


- Improving the Drug Development Process
- Pre-Clinical Innovation: Testing & Predictive Models
- Repurposing Drugs
- Re-Engineering the Clinical & Translational Process
- Accelerating & Supporting Rare Diseases Research
- Partnerships with Stakeholder Groups

*Obviously - overlap among the areas.
Feedback will be integrated.*

Continuing the discussion today...



Improving the Drug Development Process



Some possible RFI topics raised on call:

- Importance of inter-operability of bioinformatic systems
- Integrating patient data into pre-clinical research
- Focus on the precompetitive space
- Expanding therapeutic modalities


Pre-Clinical Innovation: Testing & Predictive Models

- Some possible RFI topics raised on call:
 - Approximating the human condition
 - Range of data needed for robust models
 - Innovative mechanisms for data collection and analysis
 - Engaging patient community in study design




Re-Engineering the Clinical & Translational Process

- Some possible RFI topics raised on call:
 - Connecting research and researchers along the translational science spectrum (“de-siloizing”)
 - Measuring innovation in translation
 - Skillsets and core competencies needed in translational science
 - Defining and developing clinical informatics



Repurposing Drugs

- Some possible RFI topics raised on call:
 - Systematic approaches
 - Innovative partnerships to facilitate repurposing
 - Involving the community in repurposing efforts



Accelerating & Supporting Rare Diseases Research

Some possible RFI topics raised on call:

- Examination of commonalities
- Defining rare diseases in an 'omics era
- Engagement of new partners
- Patient-driven research



Partnerships with Stakeholder Groups

Some possible RFI topics raised on call:

- Engaging with the patient community: a bi-directional process
- Nature of the “on-ramp”
- Innovative partnership models
- Modern communication and educational tools



Other Thematic Areas?



What we need next from Council/CAN RB

- Please send any additional comments on key topics/questions for stakeholder engagement in the next 10 days
- When released, publicize and encourage your networks to respond to RFI and to participate in subsequent Town Hall webinars
- Provide your own feedback



“It’s a Team Sport”

NCATS Strategic Planning Team



Penny
Burgoon



Taylor
Gilliland



Christine
Cutillo



Cindy
McConnell



Megan
Cowles

- 250+ NCATS staff who participated in small group discussions
- Council and CAN Review Board members